These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25770235)

  • 1. Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study.
    Morris S; Patel N; Baio G; Kelly L; Lewis-Holmes E; Omar RZ; Katona C; Cooper C; Livingston G
    BMJ Open; 2015 Mar; 5(3):e007382. PubMed ID: 25770235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare utilization and monetary costs associated with agitation in UK care home residents with advanced dementia: a prospective cohort study.
    Buylova Gola A; Morris S; Candy B; Davis S; King M; Kupeli N; Leavey G; Moore K; Nazareth I; Omar R; Vickerstaff V; Jones L; Sampson EL
    Int Psychogeriatr; 2020 Mar; 32(3):359-370. PubMed ID: 31948510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study.
    Costa N; Wübker A; De Mauléon A; Zwakhalen SMG; Challis D; Leino-Kilpi H; Hallberg IR; Stephan A; Zabalegui A; Saks K; Molinier L; Wimo A; Vellas B; Sauerland D; Binot I; Soto ME;
    J Am Med Dir Assoc; 2018 Jan; 19(1):95.e1-95.e10. PubMed ID: 29275939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England - The Managing Agitation and Raising QUality of LifE in Dementia (MARQUE) study.
    Panca M; Livingston G; Barber J; Cooper C; La Frenais F; Marston L; Cousins S; Hunter RM
    PLoS One; 2019; 14(2):e0211953. PubMed ID: 30807569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
    Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derivation of a brief measure of agitation and aggression in Alzheimer's disease.
    Dennehy EB; Kahle-Wrobleski K; Sarsour K; Milton DR
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):182-9. PubMed ID: 22511516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia.
    Van der Mussele S; Le Bastard N; Saerens J; Somers N; Mariën P; Goeman J; De Deyn PP; Engelborghs S
    Aging Ment Health; 2015; 19(3):247-57. PubMed ID: 24962058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence.
    Rubio-Valera M; Luciano JV; Ortiz JM; Salvador-Carulla L; Gracia A; Serrano-Blanco A
    BMC Psychiatry; 2015 Mar; 15():35. PubMed ID: 25881240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.
    Senanarong V; Cummings JL; Fairbanks L; Mega M; Masterman DM; O'Connor SM; Strickland TL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):14-20. PubMed ID: 14560060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
    Herrmann N; Gauthier S; Boneva N; Lemming OM;
    Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.